Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Egetis Therapeutics, Audiocast, Q4'25

By Inderes2/26/2026, 9:00 AM
Egetis Therapeutics

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Nicklas Westerholm
00:00 - 05:36

Good morning everyone, and a warm welcome to our Quarter 4 results call planned for the coming 30 minutes. With me today, I also have our CFO, Yilmaz Mahshid; Henrik Krook, Vice President, Commercial Operations; Anny Bedard, President, North America; and Karl Hård, Vice President, Investor Relations. Let us turn our attention to the topics being covered today. But first, let me start by saying that I'm incredibly pleased with the past year and also the deliverables post the period. The completion of the US rolling NDA in January 2026 for Emcitate, on the back of a successful pre-NDA meeting and a breakthrough designation granted by the FDA, leads us to an anticipated regulatory decision in September this year. The commercial performance showed Emcitate revenue during 2025 amounted to 62.3 Swedish million kronor and a 40% increase at constant exchange rate versus 2024. And also in Japan, where we have a license agreement with Fujimoto Pharmaceutical Corporation for the development and commercialization of tiratricol there. Fujimoto completed in December a so-called pre-application consultation for drugs with the Japanese PMDA. The NDA in Japan is expected to utilize the existing data generated from the global Clinical Development program. Moreover, Henrik and Anny will provide an update on commercialization in Europe and launch preparations in the US. And then Yilmaz at the end will provide an update on our financial performance. But first, let me summarize. The year 2025 was historic, with very strong execution that led to a number of significant milestones delivered. First, Emcitate was approved in EU in February as the first and only treatment for patients with MCT8 deficiency, and subsequently we initiated launch in the first country, Germany, in May 2025. In July, a breakthrough designation was granted by the FDA. The breakthrough designation was granted by the agency's review of a detailed analysis of the entire survival data set from the international Real World Cohort Study, the so-called EMC Survival Study by the Erasmus Medical Center, which demonstrated a significant and substantial improvement in survival in tiratricol treated versus untreated MCT8 deficiency patients. On the back of the breakthrough designation, FDA granted a so-called Pre-NDA meeting that took place in October with a very successful outcome. First, the NDA for Emcitate for the treatment of MCT8 deficiency will be based on currently available data, which means data included from Triac Trial I, Triac Trial II, ReTRIACt, the EMC Cohort Study, the EMC Survival Study, as well as the U.S. Expanded Access Program. So all in all, a very large and robust data set considering an ultra rare condition. Second, the FDA agreed that in NDA submission data from the ReTRIACt study will complement the existing data from the EMC Survival Study and the other clinical components I just referred to. Therefore, the ReTRIACt study was closed and data accrued was included in the NDA as agreed with the FDA. And lastly, the agency agreed to submit a rolling New Drug Application for Emcitate. So in November we announced the positive results from the ReTRIACt study. The results demonstrate a statistically significant difference in the rate of change in serum T3 in patients randomized to withdraw, i.e. Placebo versus in patients continuing therapy. Subsequent to that, we initiated the rolling NDA for Emcitate on the 19th of December with the submission of the preclinical and CMC sections, and completed the NDA on the 29th of January this year by submitting the clinical sections. Looking ahead, the FDA is now expected to validate within 60 days whether the NDA dossier is complete. Since Emcitate has both Fast Track Designation and Breakthrough Therapy Designation, we have requested a priority review which, if granted, would result in the FDA's review being completed within six months after the validation period, and hence a regulatory decision is expected in September 2026. So with that, I will hand over to Henrik for an update on commercialization in Europe. Hendrik, over to you. Thank you, Nicklas.

Henrik Krook
05:36 - 09:28

Good morning, everyone. I would like to start with some reflections on 2025. First, a reminder of what we have discussed earlier. In Europe, the national pricing and reimbursement processes are complex and take time. Anyway, the 2025 Emcitate revenue was 40% higher at constant exchange rates than the revenue we generated through early access. In 2025, the revenue was primarily generated in Germany, combined with successfully implemented alternative reimbursement solutions in countries such as Austria, Poland, and Switzerland. Overall, this demonstrates that our commercialization strategy is delivering tangible results and expanding access to Emcitate for patients. Turning to pricing and reimbursement, we have made advancements across our key European focus markets Germany, France, Spain and Italy. Starting with Germany. The pricing and reimbursement process is progressing well and we expect a final reimbursed price in Q2. In Germany, we launched Emcitate in parallel with the ongoing pricing and reimbursement process, and thanks to our focused activities during the year, we were able to double the number of identified patients in Germany and initiate treatment in more patients. We continue to develop this market through meetings with physicians, congress presentations, and educational initiatives. In France, we are now preparing for a resubmission. This dossier will be strengthened compared to the initial filing and will include additional clinical data such as results from the ReTRIACt study, as well as survival data. In Spain, the generation of additional local data for the national dossier is progressing well. This work is an important part of optimizing the pricing and reimbursement process and ensuring that the value of Emcitate is well supported in the national assessment process. In Italy, we have made Emcitate available to patients as of November last year through a regional launch. This will be complemented by the initiation of a national pricing and reimbursement process later during the year. More broadly, across Europe this year, we will continue to move towards funded routes in an increasing number of countries such as Belgium, the Nordics and Portugal. This includes named patient sales where possible while in parallel preparing for national health technology assessments in markets where that is considered the most appropriate long-term solution. In the fourth quarter, we also made important progress in our distribution partnering. In October, we signed an agreement with Taiba rare to enable access and named patient sales of Emcitate in the Gulf region. In addition, we expanded our existing partnership with Er-Kim, extending it from Türkiye to also cover central, eastern and southeastern Europe. And I'm pleased with how these collaborations are developing. During Q4, we received our first order from Er-Kim for Türkiye, and both Er-Kim and Taiba are actively identifying patients in their respective territories and are now in the process of initiating funded treatment to more patients. And with that, I would like to hand over to Anny for an update on the launch preparations in the US.

Anny Bedard
09:30 - 14:00

Thank you, Henrik, and good morning, everyone. Let me now turn to the United States, which is our priority commercial market and also the foundation for our long-term growth strategy as we approach the anticipated regulatory approval in the third quarter of this year. Our focus is clear, which is to translate approval into rapid uptake and durable value creation. Over the past several quarters, we've advanced each critical launch pillar and shifted from infrastructure build out to execution readiness. We're continuing to build stronger relationships across endocrinology, neurology, and genetics within the established referral network. And as a result, and with the support of key opinion leaders and advocacy partners, awareness and recognition of MCT8 deficiency are steadily increasing. We're seeing steady growth in patient identification with more than 100 confirmed diagnosed patients to date, which we view as a strong leading indicator of the market formation. In rare disease, awareness is typically limited prior to the first approval therapy. Once a treatment becomes available, identification and diagnosis tend to accelerate and that dynamic creates meaningful upside. To date, we've taken a focused and disciplined approach to the US market development. And even with measured investment, the diagnosis rate is trending upwards. Importantly, we believe physician awareness remains below its full potential, representing a clear opportunity for future growth. And as we increase our investment in education, field presence, and targeted engagement, we're confident that we will continue to grow awareness, drive additional diagnoses, and further strengthen the foundation for launch. Our expanded access program has now grown to 17 active specialist sites nationwide, which reflects both the severity of the condition and the strong clinical engagement; furthermore, beyond patient access, this program allows us to refine logistics, site coordination, and patient services in a real-world setting. And we are actively preparing the transition from the expanded access to commercial supply to ensure continuity upon approval and preserve early momentum. Our market access preparation has matured significantly, and we now have a much clearer view of payer expectations and coverage dynamics. And we're refining our pricing and value strategy through benchmarking against comparable orphan drug launches. At the same time, our specialty pharmacy and patient support infrastructure is being implemented to ensure day one readiness. The objective here is to enable timely coverage and minimize friction from prescription to treatment initiation. We've remained disciplined in our investment approach, and based on constructive FDA progress, we've appropriately accelerated launch investment. We have an experienced rare disease leadership team in place across medical, market access and commercial, and our regional medical directors are active in the field, engaging key referral centers and preparing the clinical community. By approval, we expect a team of about 25 US-based professionals, a focused team built specifically for a rare disease launch. We're now entering the approval phase fully prepared. We have patient visibility, which is increasing. Specialists are engaged. Real-world experience is expanding, payer readiness is advanced, and our launch infrastructure is in place. So right now our team is aligned, our momentum is building, and we're focused on disciplined execution to ensure full readiness and approval. I will now hand it over to our CFO, Yilmaz Mahshid, for the financial overview.

Yilmaz Mahshid
14:02 - 17:45

Over the past several quarters, we've advanced each critical launch pillar and shifted from infrastructure build-out to execution readiness. Annie. To start with, in the financial section, all numbers unless called out are in our reporting currency. Swedish krona. Revenue for the 12 months was 62.4 million, versus 46.1 million in the same period last year, of which 62.3 million is attributed to Emcitate and corresponds to a year-over-year growth of 40% in constant exchange rates. Revenue for the fourth quarter of the year was 17.9 million versus 10.8 million in the same period last year, all of which is attributed to Emcitate and corresponds to a year over year growth of 74% in constant exchange rates. As mentioned in our latest call and worth reminding again, the gross profit margin is visibly lower than historical figures, both for the 12 months and the fourth quarter. This is attributed to the positive approval in Europe and subsequent depreciation of balance sheet R&D. As a consequence, the COGS line item not only includes the recurring royalty payments, but also non-recurring milestone payments of approximately 3.5 million to Erasmus Medical Center, as well as 33.7 million of intangible R&D. The depreciation is a non-cash item, and it was initiated at the end of Q1 2025. In an apples-to-apples comparison, adjusting for the one-time payments and depreciation-adjusted gross profit is 49.6 million for the 12 months, a significant improvement not only nominally but also on the gross margin level versus the corresponding period, and we hope to improve this further post the US launch. Operating results were slightly lower for the 12 months, at approximately -340 million versus -329 million in the corresponding period. While results after tax were nearly identical for the 12 months of the year at negative 343 million versus -344 million, due to fluctuations in some of the financial line items, especially the revaluation of the convertible right, which continues to fluctuate with the share price. Remember that this is also a non cash item in the quarter. The R&D team worked intensely with the FDA submission and the closeout of the ReTRIACt study. Hence, we have a year-over-year one-off higher R&D cost of approximately 18 million. For the 12 months, cash flow from operating activities was at -267 million versus -227.9 million. Also, as you may have noticed, we continue to repay our debt and report 29.3 million in repayment for the 12 months. All in all, cash flow for the 12 months was approximately -130 million versus positive 42 million in the corresponding period. And the cash position in December 2025 was 215.8 million versus 351 million last year. Also gratifying to see that we strengthened the cash position further through the great support from our existing shareholders and new shareholders through a directed issue carried out on October 2nd in Q4 2025. With that, I will hand back to Nick.

Nicklas Westerholm
17:47 - 19:46

Revenue for the fourth quarter of the year was 17.9 million versus 10.8 million in the same period last year, of which all is attributed to Emcitate and corresponds to a year-over-year growth of 74% in constant exchange rates. Yilmaz. So let's turn our attention to the future then on the back of a strong execution in 2025. We're very well positioned for 2026 and onwards with the completed US NDA submission. We have reached a critical milestone towards making the first treatment for MCT8 deficiency available in the US. Our most important market here. I would like to take the opportunity to thank patients and families who participated in our clinical trials, the investigators and their teams and our colleagues at Egetis Therapeutics for their diligence and dedication over the last couple of years in helping us deliver Emcitate to patients affected by this rare genetic condition. The year 2026 will bring several important milestones; our team is really focused on the following key priorities. Working closely with the FDA during the review of the Emcitate NDA, with the goal of approval in the second half of 2026, and subsequently being able to monetize the Priority Review Voucher. As you've heard from Anny, preparing the US launch, including building up the commercial and Medical Affairs infrastructure, successfully launching Emcitate in the US in the fourth quarter, subject to approval by the FDA, and continuing to optimize pricing and reimbursement and continuing the rollout of Emcitate in Europe. Furthermore, with Emcitate US NDA completed for MCT8 deficiency, we will further evaluate subsequent clinical development for Emcitate in the next indication RTH-beta. So with that, I'll hand over to the operator for the Q&A session. Revenue for the fourth quarter of the year was 17.9 million versus 10.8 million in the same period last year, all of which is attributed to Emcitate and corresponds to a year-over-year growth of 74% in constant exchange rates.

Operator
19:47 - 20:05

If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Chiara Monteroni from Van Lanschot Kempen. Please go ahead.

Chiara Monteroni
20:08 - 20:53

Hi Tim, thanks for taking my questions. A couple for me, if I may. The first one. What is your latest thinking on the US pricing strategy for Emcitate, especially in the context of similar small molecule drugs with a survival benefit that are now achieving prices approaching $1 million per patient per year. And the second one would be, if you could comment on the possible Emcitate expansion into RTH-beta, how does the possible clinical development look like, timeline wise. Any outstanding items that could influence the start of a clinical study or not? If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue.

Nicklas Westerholm
20:54 - 22:19

If you wish to ask a question, please dial #5 on your telephone keypad to enter the queue. Kiara. And I'll start off with the US pricing perspective and the US opportunity and then hand over to Annie for further comments, but rightly so. Kiara, as you commented, the US market will be the most important market for Egetis and Emcitate, driven by swift access. Not just price points, but also swift access. You heard from Henrik referring to the pricing and reimbursement processes in Europe, which are lengthy. It takes time and it's 26 different national pricing and reimbursement processes one needs to walk through. So, the U.S. is very attractive, considering that access in general will span from 0 to 6 months based on a state-by-state basis, with a payer mix skewed towards Medicaid when it comes to price points. The team, together with Annie, has done some diligent work, including market research, over the last couple of years, and rightly so. As you said, even though we don't give any guidance, when you look at relevant analogues in the review we have done, you're looking at price ranges between 700,000 USD up until a million and above US dollars per patient per annum. So, of course, it's a very, very attractive opportunity for us. But Annie, please comment and build.

Anny Bedard
22:21 - 24:10

I thank you. I think you've said that the key elements in terms of the opportunity that the US offers in terms of pricing, and our key focus is really going to be on the value that Tiratricol brings, the severity of the disease, the fact that it's an ultra rare condition and also the significant unmet need, and that will really drive the framework for our pricing. We've done a lot of work, and as I mentioned, significantly advanced our progress for market access. And we've consulted with several external access experts. And we also validated what will be the key requirements and the evidence that these payers will be requesting, as well as the payer dynamic and the policy considerations. And that has been taken into our consideration as well for the pricing, because at the end of the day, what we want to achieve is really to strike a balance between the price and the accessibility of the drug. And as Nick mentioned, in terms of price range, it's hard for us to say more at this time, but it will probably sit in that range of the analogues that we've been assessing. So as we progress towards the launch, we'll be providing more detail on that. But as you can imagine, we're looking at a potential launch at the end of the year. So we still have some work to do in order to refine our pricing strategy. But that's pretty much the approach we're taking.

Nicklas Westerholm
24:12 - 25:14

Thank you, Anny. And then to your second question. Chiara, RTH-beta. So this is an opportunity we're very excited about. And it fits well with our strategy for building a sustainable rare disease company. As I'm sure you're familiar with, over the last couple of years, there have been a couple of natural history papers published on the disease, illustrating also in this condition a reduced life expectancy. Furthermore, in September, there was a scientific article published describing clinical benefits of treatment with Emcitate in this condition. RTH-beta. So for us, this is an exciting opportunity. We are now starting to further advance and build our clinical development plan in this condition, with the ambition to have one pivotal trial aligned with the EMA and FDA for registration and of course, initiate that as soon as possible. Caveat to investment decision by the board, of course. I hope that answered your questions, Chiara.

Chiara Monteroni
25:14 - 25:17

Chiara, RTH-beta. But as you can imagine, we're looking at a potential launch at the end of the year. Chiara RTH-beta. Very helpful.

Nicklas Westerholm
25:18 - 25:21

Do you have any updates on the number of patients that have been identified in the US in 2025. Let's move to the next question then. Operator, please.

Operator
25:25 - 25:29

The next question comes from Oscar Heffernan from Stifel. So as we progress towards the launch, we'll be providing more detail on that.

Oscar Heffernan
25:31 - 25:56

Yes. So as we progress towards the launch, we'll be providing more detail on that. Hi, Tim. Do you have any updates on the number of patients that have been identified in the US in 2025? And then, as a follow-up to that, you mentioned that the approval stage would positively impact the rate of diagnosis. So my question is, to what degree do you currently forecast patient identification to ramp up in the US? Post-approval. So my question is, to what degree do you currently forecast patient identification to ramp up in the US?

Nicklas Westerholm
25:58 - 26:05

Sorry, Oscar, you were breaking up a bit. So I had a bit of difficulty hearing your question. If you don't mind repeating it, please.

Oscar Heffernan
26:07 - 26:08

Yeah, sure. Is it better now?

Nicklas Westerholm
26:09 - 26:10

I think so, yeah. Please.

Oscar Heffernan
26:11 - 26:21

All right, let's try it again. So, it was just regarding the number of patients identified in the US in 2025, and then I have a follow up on that, but I can wait.

Nicklas Westerholm
26:22 - 27:49

Yeah. When it comes to the number of diagnosed patients in the US, if I heard you correctly, again, as Annie mentioned, the team has been very diligently identifying and ensuring diagnosis of patients over the last couple of years. One should recognize that up until October we had had a very, very limited infrastructure in the US, which we have now invested in, and we have four regional medical affairs directors in place early this year to further engage with key opinion leaders and stimulate patient identification and diagnosis. What we know today is that we have more than 140 diagnosed patients in the US that has increased substantially since 2022, where we knew about 28 people diagnosed, but also at the end of 2024, we called out around 100 patients being diagnosed. I think this is a huge effort by a very limited team. And I know that already this year, the team has identified a handful of patients. Hopefully that answered your question, Oscar. And we also see that we will find further patients as we strengthen our infrastructure and become more present in the US. But, Anny, I don't know if you want to add anything. Please.

Anny Bedard
27:50 - 28:14

No, I think that's pretty much it. And it's a rare condition; typically before the launch, awareness is still relatively low. And that's, that's common. But with the efforts that we're doing, we are very confident that we will quickly identify and activate the majority of the patients post-launch.

Oscar Heffernan
28:17 - 28:17

So my question is, to what degree do you currently forecast patient identification to ramp up in the US?

Nicklas Westerholm
28:18 - 28:19

My question is, to what degree do you currently forecast patient identification to ramp up in the US? Sorry.

Oscar Heffernan
28:19 - 28:30

Just maybe one follow-up. Henrik mentioned that the identification in Germany doubled this year. Do you think that getting Emcitate approved in the market changed the diagnosis dynamic there?

Nicklas Westerholm
28:34 - 28:34

Yeah.

Henrik Krook
28:35 - 29:20

Yeah. Hi, Henrik Krook. I think it's many different things contributing to that. We identified more patients in Germany after the approval, definitely, because then there is an incentive for physicians to find patients when a treatment is available and correctly diagnose them. And secondly, I think the activities that we have done in the field, more engagement with HCPs, definitely also contributed to finding those patients. And that is, I think, what we can expect to see also now with us, when we will have four regional medical directors in the field and expanding the team further during this year.

Oscar Heffernan
29:23 - 29:24

Henrik mentioned that the identification in Germany doubled this year. Do you think that getting Emcitate approved in the market changed the diagnosis dynamic there?

Nicklas Westerholm
29:24 - 29:29

Thank you Oscar. And then we'll move to the last question. Operator, please.

Operator
29:31 - 29:35

The next question comes from Arvid Nikator from DNB Carnegie. Henrik mentioned that the patient identification in Germany doubled this year.

Arvid Nikator
29:38 - 30:13

Good morning, and thanks for taking my questions. I had two, so I'll try my luck. And so the first one goes on costs with the conclusion of ReTRIACt. How much of a step down should we expect in Q1? Should we expect opex to return closer to Q2 and Q3 levels? And secondly, if you could just briefly comment on the pace of patient identification in the US, how does this trajectory compare to Europe? Is it broadly similar right now, or are you continuing to see a significantly faster rate of case finding? Henrik mentioned that the identification in Germany doubled this year.

Nicklas Westerholm
30:15 - 31:15

Henrik mentioned that the identification in Germany doubled this year. So if we start with the cost question, then I appreciate that you're noting a somewhat increased cost in Quarter 4, driven mainly by R&D. And that's more as a one-off item driven by the close out of the ReTRIACt study. And then of course, the very intense activities related to the FDA submission. So one would assume that from an R&D perspective, we'll see a drop in costs going forward. However, to a certain extent, that will be offset by the increased investments in the U.S., which are flexible costs and will be driven by opportunity and gated on some certain milestones. But as you know, we don't give any further guidance on cost base going forward, but it's reasonable to assume that you will see a bit of a drop in quarter one this year compared to quarter four. From a cost perspective, I don't know if you have anything to add.

Yilmaz Mahshid
31:16 - 31:19

No. Thanks, Nick. I think you mentioned the essence of it.

Nicklas Westerholm
31:22 - 32:04

So, moving to your second question then, around patient identification in the US versus Europe. And I think there are a couple of components I will shortly hand over to Anny. But as Henrik said, we definitely have seen here in Europe, in Germany, especially when we have an approved product that we can refer to and have more presence in the market. The number of patients being identified and known to us has increased significantly. We have already seen a bit of that in the US last year, where we have seen an increase in the number of identified patients in the US as well. But Anny, please further elaborate. From your perspective, you're closer to the market.

Anny Bedard
32:04 - 33:00

Maybe just to give a bit more color in terms of where these patients are, it is almost exclusively in the major pediatric academic centers. So we've built our footprint in the US, really around those sites so that we can access as quickly as possible. And as we've mentioned, we've already identified 140 genetically confirmed patients. We have our expanded access that is currently active in 17 sites across the US, and that allows us to keep a close connection with those treating physicians. So, we're confident that the pace has been good. But with the increased resource that we're putting in place right now, we're very confident that we will accelerate that pace before the launch.

Nicklas Westerholm
33:01 - 33:23

Thank you, Anny. And I think, all in all, it's reasonable to assume that the number of diagnosed patients known to us by Q4 year-end, where we assume a potential launch in the US, will be substantially higher than the number we refer to today, i.e. 140 patients. So so moving to your second question then around patient identification in the US versus Europe. Arvind.

Arvid Nikator
33:24 - 33:25

No. Thanks guys.

Nicklas Westerholm
33:26 - 33:31

But as you know, we don't give any further guidance on cost base going forward, but it's reasonable to assume that you will see a bit of a drop in quarter one this year compared to quarter four. And operator, I think this takes us to the end of the call. Moving to your second question then around patient identification in the US versus Europe.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…